Rothschild & Co Redburn Downgrades Moderna (NASDAQ:MRNA) to Sell

Moderna (NASDAQ:MRNA) was downgraded by stock analysts at Rothschild & Co Redburn from a “neutral” rating to a “sell” rating in a report released on Thursday, MarketBeat reports. They currently have a $81.00 price objective on the stock. Rothschild & Co Redburn’s price objective suggests a potential downside of 46.29% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. UBS Group cut shares of Moderna from a “neutral” rating to a “sell” rating in a report on Thursday. The Goldman Sachs Group increased their price objective on Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 19th. Finally, William Blair began coverage on Moderna in a research report on Friday, August 28th. They set an “outperform” rating for the company. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $76.72.

Moderna Stock Down 2.2%

MRNA stock opened at $150.81 on Thursday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $60.21 billion, a PE ratio of -18.87 and a beta of 1.10. Moderna has a twelve month low of $22.28 and a twelve month high of $176.66. The stock has a 50-day simple moving average of $82.40 and a two-hundred day simple moving average of $62.12.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same period in the prior year, the business posted ($2.13) earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Moderna will post -6.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

A number of hedge funds have recently made changes to their positions in the stock. Allied Private Wealth LLC bought a new position in Moderna in the second quarter valued at $30,000. Archer Investment Corp bought a new stake in Moderna during the second quarter worth about $36,000. Canton Hathaway LLC purchased a new position in shares of Moderna in the 1st quarter worth about $31,000. Frazier Financial Advisors LLC purchased a new position in shares of Moderna in the 2nd quarter worth about $45,000. Finally, Freestone Grove Partners LP bought a new position in shares of Moderna during the 2nd quarter valued at about $46,000. 75.33% of the stock is owned by institutional investors.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s phase 3 melanoma data strengthened the investment case for Intismeran, the companies’ individualized cancer vaccine. The 50/50 partnership gives Moderna access to Merck’s commercial infrastructure, although the longer-term upside depends on expanding the therapy beyond melanoma into additional tumor types. Moderna: Massive Asymmetry About What The mRNA Is!
• Positive Sentiment: The FDA approval of a new adult mRNA flu vaccine adds a commercial opportunity and reinforces Moderna’s position in mRNA vaccine technology. The approval, together with the melanoma results, helped drive recent investor interest. Moderna Stock Climbs Following Melanoma Trial Success and Vaccine Approval
• Positive Sentiment: Brookline Capital Markets raised its EPS forecasts for the third and fourth quarters of 2026, fiscal 2026, fiscal 2027 and fiscal 2028, while maintaining a Buy rating. Its forecast now turns profitable in 2028, with estimated EPS of $0.62. Moderna analyst estimates
• Positive Sentiment: Heavy short interest and unusually high call-option activity are supporting a potential short-squeeze narrative. Recent call purchases exceeded average daily volume, indicating speculative bullish positioning. 15 Stocks to Watch With Short Squeeze Potential

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.